Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tito Fojo

Showing results (181-190 of 237) with videos related to

Pageof 24
Sort By:
Journal of Surgical Oncology|December 23, 2011
Operative management for recurrent and metastatic adrenocortical carcinomaNicole M Datrice, Russell C Langan, R Taylor Ripley, et al.
Mutation Research|June 2, 2005
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administrationV Koneti Rao, Turid Knutsen, Thomas Ried, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLCLaurent Dercle, Matthew Fronheiser, Naiyer A Rizvi, et al.
Endocrine-Related Cancer|December 15, 2011
False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic diseaseJay S Fonte, Jeremyjones F Robles, Clara C Chen, et al.
Ebiomedicine|August 24, 2024
Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analysesHarshraj Leuva, Mengxi Zhou, Nader Jamaleddine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five daysJame Abraham, Manish Agrawal, Susan Bakke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2010
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacyWilfred D Stein, James L Gulley, Jeff Schlom, et al.
Cancer|May 17, 2002
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonistJame Abraham, Susan Bakke, Ann Rutt, et al.
Cancer Research|October 19, 2005
Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell lineKevin G Chen, Yan C Wang, Marci E Schaner, et al.
Leukemia & Lymphoma|September 21, 2025
From dimensions through dynamics to outcomes - lymph nodes and skin assessments predict CTCL outcomesAlexander Kaminsky, Lauren M Fahmy, Zaid Bilgrami, et al.
Pageof 24

Showing results (181-190 of 237) with videos related to

Sort By:
Pageof 24
Journal of Surgical Oncology|December 23, 2011
Operative management for recurrent and metastatic adrenocortical carcinomaNicole M Datrice, Russell C Langan, R Taylor Ripley, et al.
Mutation Research|June 2, 2005
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administrationV Koneti Rao, Turid Knutsen, Thomas Ried, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLCLaurent Dercle, Matthew Fronheiser, Naiyer A Rizvi, et al.
Endocrine-Related Cancer|December 15, 2011
False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic diseaseJay S Fonte, Jeremyjones F Robles, Clara C Chen, et al.
Ebiomedicine|August 24, 2024
Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analysesHarshraj Leuva, Mengxi Zhou, Nader Jamaleddine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five daysJame Abraham, Manish Agrawal, Susan Bakke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2010
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacyWilfred D Stein, James L Gulley, Jeff Schlom, et al.
Cancer|May 17, 2002
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonistJame Abraham, Susan Bakke, Ann Rutt, et al.
Cancer Research|October 19, 2005
Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell lineKevin G Chen, Yan C Wang, Marci E Schaner, et al.
Leukemia & Lymphoma|September 21, 2025
From dimensions through dynamics to outcomes - lymph nodes and skin assessments predict CTCL outcomesAlexander Kaminsky, Lauren M Fahmy, Zaid Bilgrami, et al.
Pageof 24